With increasing number of mutations there was a decrease in response rates, but this difference did not reach statistical significance (62%, 55%, 46%, and 43% for 0, 1, 2–3, and >3 mutations present, respectively).
← all excerpts
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.
1
—
—